

IPV

Poliovirus Vaccine Inactivated

IPOL[®]

R_x only



1 AHFS Category: 80:12

2 DESCRIPTION

3 IPOL[®], Poliovirus Vaccine Inactivated, produced by Sanofi Pasteur SA, is a sterile suspension of
4 three types of poliovirus: Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett). IPOL
5 vaccine is a highly purified, inactivated poliovirus vaccine with enhanced potency. Each of the
6 three strains of poliovirus is individually grown in vero cells, a continuous line of monkey kidney
7 cells cultivated on microcarriers. (1) (2) The cells are grown in Eagle MEM modified medium,
8 supplemented with newborn calf serum tested for adventitious agents prior to use, originated from
9 countries free of bovine spongiform encephalopathy. For viral growth, the culture medium is
10 replaced by M-199, without calf serum. This culture technique and improvements in purification,
11 concentration, and standardization of poliovirus antigen produce a more potent and consistent
12 immunogenic vaccine than the inactivated poliovirus vaccine (IPV) available in the US prior to
13 1988. (3) (4)

14

15 After clarification and filtration, viral suspensions are concentrated by ultrafiltration, and purified
16 by three liquid chromatography steps; one column of anion exchanger, one column of gel
17 filtration, and again one column of anion exchanger. After re-equilibration of the purified viral
18 suspension with Medium M-199 and adjustment of the antigen titer, the monovalent viral
19 suspensions are inactivated at +37°C for at least 12 days with 1:4000 formalin.

20

1 Each dose (0.5 mL) of trivalent vaccine is formulated to contain 40 D antigen units of Type 1, 8 D
2 antigen units of Type 2, and 32 D antigen units of Type 3 poliovirus. For each lot of IPOL
3 vaccine, D-antigen content is determined *in vitro* using the D-antigen ELISA assay. IPOL vaccine
4 is produced from vaccine concentrates diluted with M-199 medium. Also present are 0.5% of 2-
5 phenoxyethanol and a maximum of 0.02% of formaldehyde per dose as preservatives. Neomycin,
6 streptomycin, and polymyxin B are used in vaccine production; and, although purification
7 procedures eliminate measurable amounts, less than 5 ng neomycin, 200 ng streptomycin, and 25
8 ng polymyxin B per dose may still be present. The residual calf serum protein is less than 1 ppm
9 in the final vaccine.

10

11 The vaccine is clear and colorless and should be administered intramuscularly or subcutaneously.

12

13 There is no latex in any component of the vial or syringe.

14

15 **CLINICAL PHARMACOLOGY**

16 Poliomyelitis is caused by poliovirus Types 1, 2, or 3. It is primarily spread by the fecal-oral route
17 of transmission but may also be spread by the pharyngeal route.

18

19 Approximately 90% to 95% of poliovirus infections are asymptomatic. Nonspecific illness with
20 low-grade fever and sore throat (minor illness) occurs in 4% to 8% of infections. Aseptic
21 meningitis occurs in 1% to 5% of patients a few days after the minor illness has resolved. Rapid
22 onset of asymmetric acute flaccid paralysis occurs in 0.1% to 2% of infections, and residual

1 paralytic disease involving motor neurons (paralytic poliomyelitis) occurs in approximately 1 per
2 1,000 infections. (5)

3

4 Prior to the introduction of inactivated poliovirus vaccines in 1955, large outbreaks of
5 poliomyelitis occurred each year in the United States (US). The annual incidence of paralytic
6 disease of 11.4 cases/100,000 population declined to 0.5 cases by the time oral poliovirus vaccine
7 (OPV) was introduced in 1961. Incidence continued to decline thereafter to a rate of 0.002 to
8 0.005 cases per 100,000 population. Of the 127 cases of paralytic poliomyelitis reported in the US
9 between 1980 and 1994, six were imported cases (caused by wild polioviruses), two were
10 “indeterminate” cases, and 119 were vaccine associated paralytic poliomyelitis (VAPP) cases
11 associated with the use of live, attenuated oral poliovirus vaccine (OPV). (6) An all IPV schedule
12 was adopted in 1999, to eliminate VAPP cases. (7)

13

14 Poliovirus Vaccine Inactivated induces the production of neutralizing antibodies against each type
15 of virus which are related to protective efficacy. Antibody response in most children were induced
16 after receiving fewer doses (8) of IPV vaccine than the vaccine available in the United States prior
17 to 1988.

18

19 Studies in developed (8) and developing (9), (10) countries with a similar enhanced IPV
20 manufactured by the same process as IPOL vaccine in primary monkey kidney cells have shown a
21 direct relationship exists between the antigenic content of the vaccine, the frequency of
22 seroconversion, and resulting antibody titer. Approval in the US was based upon demonstration of
23 immunogenicity and safety in US children. (11)

1

2 In the US, 219 infants received three doses of a similar enhanced IPV at two, four, and eighteen
3 months of age manufactured by the same process as IPOL vaccine except the cell substrate for
4 IPV was using primary monkey kidney cells. Seroconversion to all three types of poliovirus was
5 demonstrated in 99% of these infants after two doses of vaccine given at 2 and 4 months of age.
6 Following the third dose of vaccine at 18 months of age, neutralizing antibodies were present at a
7 level of $\geq 1:10$ in 99.1% of children to Type 1 and 100% of children to Types 2 and 3 polioviruses.

8 (3)

9

10 IPOL vaccine was administered to more than 700 infants between 2 to 18 months of age during
11 three clinical studies conducted in the US using IPV only schedules and sequential IPV-OPV
12 schedules. (12) (13) Seroprevalence rates for detectable serum neutralizing antibody (DA) at a
13 $\geq 1:4$ dilution were 95% to 100% (Type 1); 97% to 100% (Type 2) and 96% to 100% (Type 3)
14 after two doses of IPOL vaccine depending on studies.

15

16

1 **Table 1: US Studies with IPOL Vaccine Administered Using IPV Only or Sequential IPV-**
2 **OPV Schedules**

Age (months) for				Post Dose 2				Post Dose 3				Pre Booster				Post Booster			
2	4	6	12 to 18	Type 1	Type 2	Type 3	Type 1	Type 2	Type 3	Type 1	Type 2	Type 3	Type 1	Type 2	Type 3	Type 1	Type 2	Type 3	
Dose 1	Dose 2	Dose 3	Booster	N*	%DA**	%DA	%DA	N*	%DA	%DA	%DA	N*	%DA	%DA	%DA	N*	%DA	%DA	%DA
STUDY 1 ^{(11) ¶}																			
I(s)	I(s)	NA†	I(s)	56	97	100	97	-	-	-	-	53	91	97	93	53	97	100	100
O	O	NA	O	22	100	100	100	-	-	-	-	22	78	91	78	20	100	100	100
I(s)	O	NA	O	17	95	100	95	-	-	-	-	17	95	100	95	17	100	100	100
I(s)	I(s)	NA	O	17	100	100	100	-	-	-	-	16	100	100	94	16	100	100	100
STUDY 2 ^{(10) §}																			
I(c)	I(c)	NA	I(s)	94	98	97	96	-	-	-	-	100	92	95	88	97	100	100	100
I(s)	I(s)	NA	I(s)	68	99	100	99	-	-	-	-	72	100	100	94	75	100	100	100
I(c)	I(c)	NA	O	75	95	99	96	-	-	-	-	77	86	97	82	78	100	100	97
I(s)	I(s)	NA	O	101	99	99	95	-	-	-	-	103	99	97	89	107	100	100	100
STUDY 3 ^{(10) §}																			
I(c)	I(c)	I(c)	O	91	98	99	100	91	100	100	100	41	100	100	100	40	100	100	100
I(c)	I(c)	O	O	96	100	98	99	94	100	100	99	47	100	100	100	45	100	100	100
I(c)	I(c)	I(c) + O	O	91	96	97	100	85	100	100	100	47	100	100	100	46	100	100	100

3 * N = Number of children from whom serum was available

4 ** Detectable antibody (neutralizing titer ≥1:4)

5 † NA – No poliovirus vaccine administered

6 ¶ IPOL vaccine given subcutaneously

7 § IPOL vaccine given intramuscularly

8 I IPOL vaccine given either separately in association with DTP in two sites (s) or combined (c) with DTP in a
9 dual chambered syringe

10 O OPV

11

1 In one study, (13) the persistence of DA in infants receiving two doses of IPOL vaccine at 2 and 4
2 months of age was 91% to 100% (Type 1), 97% to 100% (Type 2), and 93% to 94% (Type 3) at
3 twelve months of age. In another study, (12) 86% to 100% (Type 1), 95% to 100% (Type 2), and
4 82% to 94% (Type 3) of infants still had DA at 18 months of age.

5

6 In trials and field studies conducted outside the US, IPOL vaccine, or a combination vaccine
7 containing IPOL vaccine and DTP, was administered to more than 3,000 infants between 2 to 18
8 months of age using IPV only schedules and immunogenicity data are available from 1,485
9 infants. After two doses of vaccine given during the first year of life, seroprevalence rates for
10 detectable serum neutralizing antibody (neutralizing titer $\geq 1:4$) were 88% to 100% (Type 1); 84%
11 to 100% (Type 2) and 94% to 100% (Type 3) of infants, depending on studies. When three doses
12 were given during the first year of life, post-dose 3 DA ranged between 93% to 100% (Type 1);
13 89% to 100% (Type 2) and 97% to 100% (Type 3) and reached 100% for Types 1, 2, and 3 after
14 the fourth dose given during the second year of life (12 to 18 months of age). (14)

15

16 In infants immunized with three doses of an unlicensed combination vaccine containing IPOL
17 vaccine and DTP given during the first year of life, and a fourth dose given during the second year
18 of life, the persistence of detectable neutralizing antibodies was 96%, 96%, and 97% against
19 poliovirus Types 1, 2, and 3, respectively, at six years of age. DA reached 100% for all types after
20 a booster dose of IPOL vaccine combined with DTP vaccine. (11) A survey of Swedish children
21 and young adults given a Swedish IPV only schedule demonstrated persistence of detectable
22 serum neutralizing antibody for at least 10 years to all three types of poliovirus. (15)

23

1 IPV is able to induce secretory antibody (IgA) produced in the pharynx and gut and reduces
2 pharyngeal excretion of poliovirus Type 1 from 75% in children with neutralizing antibodies at
3 levels less than 1:8 to 25% in children with neutralizing antibodies at levels more than 1:64. (4)
4 (14) (16) (17) (18) (19) (20) (21) (22) There is also evidence of induction of herd immunity with
5 IPV, (15) (23) (24) (25) (26) and that this herd immunity is sufficiently maintained in a population
6 vaccinated only with IPV. (26)

7

8 VAPP has not been reported in association with administration of IPOL vaccine. (27) It is
9 expected that an IPV only schedule will eliminate the risk of VAPP in both recipients and
10 contacts compared to a schedule that included OPV. (7)

11

12 **INDICATIONS AND USAGE**

13 IPOL vaccine is indicated for active immunization of infants (as young as 6 weeks of age),
14 children, and adults for the prevention of poliomyelitis caused by poliovirus Types 1, 2, and 3.
15 (28)

16

17 **INFANTS, CHILDREN AND ADOLESCENTS**

18 **General Recommendations**

19 It is recommended that all infants (as young as 6 weeks of age), unimmunized children, and
20 adolescents not previously immunized be vaccinated routinely against paralytic poliomyelitis.
21 (29) Following the eradication of poliomyelitis caused by wild poliovirus from the Western
22 Hemisphere (including North and South America) (30), an IPV-only schedule was recommended
23 to eliminate VAPP. (7)

1

2 All children should receive four doses of IPV at ages 2, 4, 6 to 18 months, and 4 to 6 years. OPV
3 is no longer available in the US and is not recommended for routine immunization. (7)

4

5 Previous clinical poliomyelitis (usually due to only a single poliovirus type) or incomplete
6 immunization with OPV are not contraindications to completing the primary series of
7 immunization with IPOL vaccine.

8

9 **Children Incompletely Immunized**

10 Children of all ages should have their immunization status reviewed and be considered for
11 supplemental immunization as follows for adults. Time intervals between doses longer than those
12 recommended for routine primary immunization do not necessitate additional doses as long as a
13 final total of four doses is reached (see **DOSAGE AND ADMINISTRATION** section).

14

15 **ADULTS**

16 **General Recommendations**

17 Routine primary poliovirus vaccination of adults (generally those 18 years of age or older)
18 residing in the US is not recommended. Unimmunized adults who are potentially exposed to wild
19 poliovirus and have not been adequately immunized should receive polio vaccination in
20 accordance with the schedule given in the **DOSAGE AND ADMINISTRATION** section. (28)

21

1 Persons with previous wild poliovirus disease who are incompletely immunized or unimmunized
2 should be given additional doses of IPOL vaccine if they fall into one or more categories listed
3 previously.

4

5 The following categories of adults are at an increased risk of exposure to wild polioviruses: (28)

6 (31)

- 7 • Travelers to regions or countries where poliomyelitis is endemic or epidemic.
- 8 • Health-care workers in close contact with patients who may be excreting polioviruses.
- 9 • Laboratory workers handling specimens that may contain polioviruses.
- 10 • Members of communities or specific population groups with disease caused by wild
- 11 polioviruses.

12

13 **IMMUNODEFICIENCY AND ALTERED IMMUNE STATUS**

14 IPOL vaccine should be used in all patients with immunodeficiency diseases and members of
15 such patients' households when vaccination of such persons is indicated. This includes patients
16 with asymptomatic HIV infection, AIDS or AIDS-Related Complex, severe combined
17 immunodeficiency, hypogammaglobulinemia, or agammaglobulinemia; altered immune states due
18 to diseases such as leukemia, lymphoma, or generalized malignancy; or an immune system
19 compromised by treatment with corticosteroids, alkylating drugs, antimetabolites or radiation.

20 Immunogenicity of IPOL vaccine in individuals receiving immunoglobulin could be impaired,
21 and patients with an altered immune state may or may not develop a protective response against
22 paralytic poliomyelitis after administration of IPV. (32)

23

1 As with any vaccine, vaccination with IPOL vaccine may not protect 100% of individuals.

2

3 Use with other vaccines: refer to **DOSAGE AND ADMINISTRATION** section for this
4 information.

5

6 **CONTRAINDICATIONS**

7 IPOL vaccine is contraindicated in persons with a history of hypersensitivity to any component of
8 the vaccine, including 2-phenoxyethanol, formaldehyde, neomycin, streptomycin, and polymyxin
9 B.

10

11 No further doses should be given if anaphylaxis or anaphylactic shock occurs within 24 hours of
12 administration of one dose of vaccine.

13

14 Vaccination of persons with an acute, febrile illness should be deferred until after recovery;
15 however, minor illness, such as mild upper respiratory infection, with or without low grade fever,
16 are not reasons for postponing vaccine administration.

17

18 **WARNINGS**

19 Neomycin, streptomycin, polymyxin B, 2-phenoxyethanol, and formaldehyde are used in the
20 production of this vaccine. Although purification procedures eliminate measurable amounts of
21 these substances, traces may be present (see **DESCRIPTION** section), and allergic reactions may
22 occur in persons sensitive to these substances (see **CONTRAINDICATIONS** section).

23

1 Systemic adverse reactions reported in infants receiving IPV concomitantly at separate sites or
2 combined with DTP have been similar to those associated with administration of DTP alone. (11)
3 Local reactions are usually mild and transient in nature.

4

5 Although no causal relationship between IPOL vaccine and Guillain-Barré Syndrome (GBS) has
6 been established, (28) GBS has been temporally related to administration of another inactivated
7 poliovirus vaccine. Deaths have been reported in temporal association with the administration of
8 IPV (see **ADVERSE REACTIONS** section).

9

10 **PRECAUTIONS**

11 **GENERAL**

12 Prior to an injection of any vaccine, all known precautions should be taken to prevent adverse
13 reactions. This includes a review of the patient's history with respect to possible sensitivity to the
14 vaccine or similar vaccines.

15

16 Health-care providers should question the patient, parent or guardian about reactions to a previous
17 dose of this product, or similar product.

18

19 Epinephrine injection (1:1000) and other appropriate agents should be available to control
20 immediate allergic reactions.

21

22 Health-care providers should obtain the previous immunization history of the vaccinee, and
23 inquire about the current health status of the vaccinee.

1

2 Immunodeficient patients or patients under immunosuppressive therapy may not develop a
3 protective immune response against paralytic poliomyelitis after administration of IPV.

4

5 Administration of IPOL vaccine is not contraindicated in individuals infected with HIV. (33) (34)

6 (35)

7

8 Special care should be taken to ensure that the injection does not enter a blood vessel.

9

10 **INFORMATION FOR PATIENTS**

11 Patients, parents, or guardians should be instructed to report any serious adverse reactions to their
12 health-care provider.

13

14 The health-care provider should inform the patient, parent, or guardian of the benefits and risks of
15 the vaccine.

16

17 The health-care provider should inform the patient, parent, or guardian of the importance of
18 completing the immunization series.

19

20 The health-care provider should provide the Vaccine Information Statements (VISs) which are
21 required to be given with each immunization.

22

1 **DRUG INTERACTIONS**

2 There are no known interactions of IPOL vaccine with drugs or foods. Concomitant
3 administration of other parenteral vaccines, with separate syringes at separate sites, is not
4 contraindicated. The first two doses of IPOL vaccine may be administered at separate sites using
5 separate syringes concomitantly with DTaP, acellular pertussis, *Haemophilus influenzae* type b
6 (Hib), and hepatitis B vaccines. From historical data on the antibody responses to diphtheria,
7 tetanus, acellular pertussis, Hib, or hepatitis B vaccines used concomitantly or in combination
8 with IPOL vaccine, no interferences have been observed on the immunological end points
9 accepted for clinical protection. (11) (16) (36) (See **DOSAGE AND ADMINISTRATION**
10 section.)

11
12 If IPOL vaccine has been administered to persons receiving immunosuppressive therapy, an
13 adequate immunologic response may not be obtained. (See **PRECAUTIONS – GENERAL**
14 section.)

15

16 **CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY**

17 Long-term studies in animals to evaluate carcinogenic potential or impairment of fertility have not
18 been conducted.

19

20 **PREGNANCY CATEGORY C**

21 Animal reproduction studies have not been conducted with IPOL vaccine. It is also not known
22 whether IPOL vaccine can cause fetal harm when administered to a pregnant woman or can affect
23 reproduction capacity. IPOL vaccine should be given to a pregnant woman only if clearly needed.

24

1 **NURSING MOTHERS**

2 It is not known whether IPOL vaccine is excreted in human milk. Because many drugs are
3 excreted in human milk, caution should be exercised when IPOL vaccine is administered to a
4 nursing woman.

5

6 **PEDIATRIC USE**

7 *SAFETY AND EFFECTIVENESS OF IPOL VACCINE IN INFANTS BELOW SIX WEEKS OF*
8 *AGE HAVE NOT BEEN ESTABLISHED.* (12) (20) (See **DOSAGE AND ADMINISTRATION**
9 section.)

10

11 In the US, infants receiving two doses of IPV at 2 and 4 months of age, the seroprevalence to all
12 three types of poliovirus was demonstrated in 95% to 100% of these infants after two doses of
13 vaccine. (12) (13)

14

15 **ADVERSE REACTIONS**

16 **Body System As A Whole**

17 In earlier studies with the vaccine grown in primary monkey kidney cells, transient local reactions
18 at the site of injection were observed. (3) Erythema, induration and pain occurred in 3.2%, 1%
19 and 13%, respectively, of vaccinees within 48 hours post-vaccination. Temperatures of $\geq 39^{\circ}\text{C}$
20 ($\geq 102^{\circ}\text{F}$) were reported in 38% of vaccinees. Other symptoms included irritability, sleepiness,
21 fussiness, and crying. Because IPV was given in a different site but concurrently with Diphtheria
22 and Tetanus Toxoids and Pertussis Vaccine Adsorbed (DTP), these systemic reactions could not
23 be attributed to a specific vaccine. However, these systemic reactions were comparable in

1 frequency and severity to that reported for DTP given alone without IPV. (12) Although no causal
2 relationship has been established, deaths have occurred in temporal association after vaccination
3 of infants with IPV. (37)

4

5 Four additional US studies using IPOL vaccine in more than 1,300 infants, (12) between 2 to 18
6 months of age administered with DTP at the same time at separate sites or combined have
7 demonstrated that local and systemic reactions were similar when DTP was given alone.

8

9

1 **Table 2 (12): Percentage of Infants Presenting with Local or Systemic Reactions at 6, 24,**
 2 **and 48 Hours of Immunization with IPOL Vaccine Administered Intramuscularly**
 3 **Concomitantly at Separate Sites with Sanofi¶ Whole-Cell DTP Vaccine at 2 and 4 Months of**
 4 **Age and with Sanofi Acellular Pertussis Vaccine (Tripedia®) at 18 Months of Age**

REACTION	AGE AT IMMUNIZATION								
	2 Months (n=211)			4 Months (n=206)			18 Months [†] (n=74)		
	6 Hrs.	24 Hrs.	48 Hrs.	6 Hrs.	24 Hrs.	48 Hrs.	6 Hrs.	24 Hrs.	48 Hrs.
Local, IPOL vaccine alone[§]									
Erythema >1"	0.5%	0.5%	0.5%	1.0%	0.0%	0.0%	1.4%	0.0%	0.0%
Swelling	11.4%	5.7%	0.9%	11.2%	4.9%	1.9%	2.7%	0.0%	0.0%
Tenderness	29.4%	8.5%	2.8%	22.8%	4.4%	1.0%	13.5%	4.1%	0.0%
Systemic*									
Fever >102.2°F	1.0%	0.5%	0.5%	2.0%	0.5%	0.0%	0.0%	0.0%	4.2%
Irritability	64.5%	24.6%	17.5%	49.5%	25.7%	11.7%	14.7%	6.7%	8.0%
Tiredness	60.7%	31.8%	7.1%	38.8%	18.4%	6.3%	9.3%	5.3%	4.0%
Anorexia	16.6%	8.1%	4.3%	6.3%	4.4%	2.4%	2.7%	1.3%	2.7%
Vomiting	1.9%	2.8%	2.8%	1.9%	1.5%	1.0%	1.3%	1.3%	0.0%
Persistent Crying	Percentage of infants within 72 hours after immunization was 0.0% after dose one, 1.4% after dose two, and 0.0% after dose three.								

5 ¶ Sanofi Pasteur Inc. formerly known as Aventis Pasteur Inc.

6 § Data are from the IPOL vaccine administration site, given intramuscularly.

7 * The adverse reaction profile includes the concomitant use of Sanofi whole-cell DTP vaccine or Tripedia vaccine
 8 with IPOL vaccine. Rates are comparable in frequency and severity to that reported for whole-cell DTP given alone.

9 † Children who have been vaccinated with Tripedia vaccine.

1

2 *Digestive System*

3 Anorexia and vomiting occurred with frequencies not significantly different as reported when
4 DTP was given alone without IPV or OPV. (12)

5

6 *Nervous System*

7 Although no causal relationship between IPOL vaccine and GBS has been established, (28) GBS
8 has been temporally related to administration of another inactivated poliovirus vaccine.

9

10 **Post-marketing Experience**

11 The following adverse events have been identified during postapproval use of IPOL vaccine.

12 Because these events are reported voluntarily from a population of uncertain size, it may not be
13 possible to reliably estimate their frequency or establish a causal relationship to vaccine exposure.

14 Adverse events were included based on one or more of the following factors: severity, frequency
15 of reporting or strength of evidence for a causal relationship.

- 16 • *Blood and lymphatic system disorders*: lymphadenopathy
- 17 • *General disorders and administration site conditions*: agitation, injection site reaction
18 including injection site rash and mass
- 19 • *Immune system disorders*: type I hypersensitivity including allergic reaction, anaphylactic
20 reaction, and anaphylactic shock
- 21 • *Musculoskeletal and connective tissue disorders*: arthralgia, myalgia
- 22 • *Nervous system disorders*: convulsion, febrile convulsion, headache, paresthesia, and
23 somnolence

- 1 • *Skin and subcutaneous tissue disorders*: rash, urticaria

2

3 **Reporting of Adverse Events**

4 The National Vaccine Injury Compensation Program, established by the National Childhood
5 Vaccine Injury Act of 1986, requires physicians and other health-care providers who administer
6 vaccines to maintain permanent vaccination records and to report occurrences of certain adverse
7 events to the US Department of Health and Human Services. Reportable events include those
8 listed in the Act for each vaccine and events specified in the package insert as contraindications to
9 further doses of that vaccine. (38) (39) (40)

10

11 Reporting by parents or guardians of all adverse events after vaccine administration should be
12 encouraged. Adverse events following immunization with vaccine should be reported by health-
13 care providers to the US Department of Health and Human Services (DHHS) Vaccine Adverse
14 Event Reporting System (VAERS). Reporting forms and information about reporting
15 requirements or completion of the form can be obtained from VAERS through a toll-free number
16 1-800-822-7967. (38) (39) (40)

17

18 **Health-care providers also should report these events to the Pharmacovigilance**
19 **Department, Sanofi Pasteur Inc., Discovery Drive, Swiftwater, PA 18370 or call 1-800-822-**
20 **2463.**

21

1 **DOSAGE AND ADMINISTRATION**

2 Parenteral drug products should be inspected visually for particulate matter and discoloration
3 prior to administration, whenever solution and container permit. The syringe or vial and its
4 packaging should be inspected prior to use for evidence of leakage, premature activation of the
5 plunger, or a faulty tip seal. If evidence of such defects are observed, the vaccine should not be
6 used. Do not remove the vial stopper or the metal seal holding it in place.

7
8 After preparation of the injection site, using a suitable sterile needle and aseptic technique,
9 immediately administer IPOL vaccine intramuscularly or subcutaneously. In infants and small
10 children, the mid-lateral aspect of the thigh is the preferred site. In older children and adults, IPOL
11 vaccine should be administered intramuscularly or subcutaneously in the deltoid area. IPOL
12 should not be combined through reconstitution or mixed with any other vaccine.

13
14 The pre-filled syringe is intended for single use only, must not be reused, and must be disposed of
15 properly and promptly following its use.

16
17 To help avoid HIV (AIDS), HBV (Hepatitis), and other infectious diseases due to accidental
18 needlesticks, contaminated needles should not be recapped or removed, unless there is no
19 alternative or that such action is required by a specific medical procedure.

20
21 Care should be taken to avoid administering the injection into or near blood vessels and nerves. If
22 blood or any suspicious discoloration appears in the syringe, do not inject but discard contents and
23 repeat procedures using a new dose of vaccine administered at a different site.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21

DO NOT ADMINISTER VACCINE INTRAVENOUSLY.

Children

The primary series of IPOL vaccine consists of three 0.5 mL doses administered intramuscularly or subcutaneously, preferably eight or more weeks apart and usually at ages 2, 4, and 6 to 18 months. Under no circumstances should the vaccine be given more frequently than four weeks apart. The first immunization may be administered as early as six weeks of age. For this series, a booster dose of IPOL vaccine is administered at 4 to 6 years of age. (41)

Use with Other Vaccines

From historical data on the antibody responses to diphtheria, tetanus, whole-cell or acellular pertussis, Hib, or hepatitis B vaccines used concomitantly with IPOL vaccine, no interferences have been observed on the immunological end points accepted for clinical protection. (11) (16) (36) (See **DRUG INTERACTIONS** section.)

If the third dose of IPOL vaccine is given between 12 to 18 months of age, it may be desirable to administer this dose with Measles, Mumps, and Rubella (MMR) vaccine and/or other vaccines using separate syringes at separate sites, (28) but no data on the immunological interference between IPOL vaccine and these vaccines exist.

1 **Use in Previously Vaccinated Children**

2 Children and adolescents with a previously incomplete series of polio vaccine should receive
3 sufficient additional doses of IPOL vaccine to complete the series.

4

5 Interruption of the recommended schedule with a delay between doses does not interfere with the
6 final immunity. There is no need to start the series over again, regardless of the time elapsed
7 between doses.

8

9 The need to routinely administer additional doses is unknown at this time. (28)

10

11 **Adults**

12 **Unvaccinated Adults**

13 A primary series of IPOL vaccine is recommended for unvaccinated adults at increased risk of
14 exposure to poliovirus. While the responses of adults to primary series have not been studied, the
15 recommended schedule for adults is two doses given at a 1 to 2 month interval and a third dose
16 given 6 to 12 months later. If less than 3 months but more than 2 months are available before
17 protection is needed, three doses of IPOL vaccine should be given at least 1 month apart.

18 Likewise, if only 1 or 2 months are available, two doses of IPOL vaccine should be given at least
19 1 month apart. If less than 1 month is available, a single dose of IPOL vaccine is recommended.

20 (28)

21

1 **Incompletely Vaccinated Adults**

2 Adults who are at an increased risk of exposure to poliovirus and who have had at least one dose
3 of OPV, fewer than three doses of conventional IPV or a combination of conventional IPV or
4 OPV totaling fewer than three doses should receive at least one dose of IPOL vaccine. Additional
5 doses needed to complete a primary series should be given if time permits. (28)

6

7 **Completely Vaccinated Adults**

8 Adults who are at an increased risk of exposure to poliovirus and who have previously completed
9 a primary series with one or a combination of polio vaccines can be given a dose of IPOL vaccine.

10

11 The preferred injection site of IPOL vaccine for adults is in the deltoid area.

12

13 **HOW SUPPLIED**

14 Syringe, without needle, 0.5 mL: NDC 49281-860-88. Supplied (10 syringes per package) as
15 package: NDC 49281-860-55.

16 Vial containing ten 0.5 mL doses: NDC 49281-860-78. Supplied as package: NDC 49281-860-10.

17

18 **STORAGE**

19 The vaccine is stable if stored in the refrigerator at 2°C to 8°C (35°F to 46°F). The vaccine must
20 not be frozen.

21 Protect from light.

1 **REFERENCES**

2

3 1 van Wezel AL, et al. Inactivated poliovirus vaccine: Current production methods and new
4 developments. *Rev Infect Dis* 6 (Suppl 2): S335-S340, 1984.

5 2 Montagnon BJ, et al. Industrial scale production of inactivated poliovirus vaccine prepared
6 by culture of Vero cells on microcarrier. *Rev Infect Dis* 6 (Suppl 2): S341-S344, 1984.

7 3 McBean AM, et al. Serologic response to oral polio vaccine and enhanced-potency
8 inactivated polio vaccines. *Am J Epidemiol* 128: 615-628, 1988.

9 4 Murdin AD, et al. Inactivated poliovirus vaccine: past and present experience. *Vaccine* 8:
10 735-746, 1996.

11 5 Sabin AB. Poliomyelitis. In Brande AI, Davis CE, Fierer J (eds) *International Textbook of*
12 *Medicine, Vol II. Infectious Diseases and Medical Microbiology.* 2nd ed. Philadelphia, WB
13 Saunders, 1986.

14 6 Prevots DR, et al. Vaccine-associated paralytic poliomyelitis in the United States, 1980-
15 1994: current risk and potential impact of a proposed sequential schedule of IPV followed
16 by OPV (Abstract #H90). In: *Abstracts of the 36th Interscience Conference on*
17 *Antimicrobial Agents and Chemotherapy.* Washington, DC. American Society for
18 Microbiology, 179, 1996.

19 7 ACIP. Updated Recommendations of the Advisory Committee on Immunization Practices.
20 Poliomyelitis Prevention in the United States. *MMWR* 49: No. RR-5, 2000.

21 8 Salk J, et al. Antigen content of inactivated poliovirus vaccine for use in a one- or two-dose
22 regimen. *Ann Clin Res* 14: 204-212, 1982.

- 1 9 Salk J, et al. Killed poliovirus antigen titration in humans. *Develop Biol Standard* 41: 119-
2 132, 1978.
- 3 10 Salk J, et al. Theoretical and practical considerations in the application of killed poliovirus
4 vaccine for the control of paralytic poliomyelitis. *Develop Biol Standard* 47: 181-198, 1981.
- 5 11 Unpublished data available from Sanofi Pasteur SA.
- 6 12 Unpublished data available from Sanofi Pasteur Inc.
- 7 13 Faden H, et al. Comparative evaluation of immunization with live attenuated and enhanced
8 potency inactivated trivalent poliovirus vaccines in childhood: Systemic and local immune
9 responses. *J Infect Dis* 162: 1291-1297, 1990.
- 10 14 Vidor E, et al. The place of DTP/eIPV vaccine in routine paediatric vaccination. *Rev Med*
11 *Virol* 4: 261-277, 1994.
- 12 15 Bottiger M. Long-term immunity following vaccination with killed poliovirus vaccine in
13 Sweden, a country with no circulating poliovirus. *Rev Infect Dis* 6 (Suppl 2): S548-S551,
14 1984.
- 15 16 Plotkin SA, et al. Inactivated polio vaccine for the United States: a missed vaccination
16 opportunity. *Pediatr Infect Dis J* 14: 835-839, 1995.
- 17 17 Marine WM, et al. Limitation of fecal and pharyngeal poliovirus excretion in Salk-
18 vaccinated children. A family study during a Type 1 poliomyelitis epidemic. *Amer J Hyg*
19 76: 173-195, 1962.
- 20 18 Bottiger M, et al. Vaccination with attenuated Type 1 poliovirus, the Chat strain. II.
21 Transmission of virus in relation to age. *Acta Paed Scand* 55: 416-421, 1966.

- 1 19 Dick GWA, et al. Vaccination against poliomyelitis with live virus vaccines. Effect of
2 previous Salk vaccination on virus excretion. *Brit Med J* 2: 266-269, 1961.
- 3 20 Wehrle PF, et al. Transmission of poliovirus; III. Prevalence of polioviruses in pharyngeal
4 secretions of infected household contacts of patients with clinical disease. *Pediatrics* 27:
5 762-764, 1961.
- 6 21 Adenyi-Jones SC, et al. Systemic and local immune responses to enhanced-potency
7 inactivated poliovirus vaccine in premature and term infants. *J Pediatr* 120: No 5, 686-689,
8 1992.
- 9 22 Chin TDY. Immunity induced by inactivated poliovirus vaccine and excretion of virus. *Rev*
10 *Infect Dis* 6 (Suppl 2): S369-S370, 1984.
- 11 23 Salk D. Herd effect and virus eradication with use of killed poliovirus vaccine. *Develop*
12 *Biol Standard* 47: 247-255, 1981.
- 13 24 Bijerk H. Surveillance and control of poliomyelitis in the Netherlands. *Rev Infect Dis* 6
14 (Suppl 2): S451-S456, 1984.
- 15 25 Lapinleimu K. Elimination of poliomyelitis in Finland. *Rev Infect Dis* 6 (Suppl 2): S457-
16 S460, 1984.
- 17 26 Conyn van Spaendonck M, et al. Circulation of Poliovirus during the poliomyelitis outbreak
18 in the Netherlands in 1992-1993. *Amer J Epidemiology* 143: 929-935, 1996.
- 19 27 Strebel PM, et al. Epidemiology of poliomyelitis in the United States one decade after the
20 last reported case of indigenous wild virus associated disease. *Clin Infect Dis* 14: 568-579,
21 1992.

- 1 28 ACIP. Poliomyelitis prevention in the United States: introduction of a sequential
2 vaccination schedule of Inactivated Poliovirus Vaccine followed by Oral Poliovirus
3 Vaccine. MMWR 46: No. RR-3, 1997.
- 4 29 WHO. Weekly Epidemiology Record 54: 82-83, 1979.
- 5 30 Certification of poliomyelitis eradication - the Americas, 1994. MMWR 43: 720-722, 1994.
- 6 31 Institute of Medicine. An evaluation of poliomyelitis vaccine poliomyelitis vaccine policy
7 options. Washington, DC. National Academy of Sciences, 1988.
- 8 32 ACIP. Immunization of children infected with human T-lymphotropic virus type
9 III/lymphadenopathy-associated virus. MMWR 35: 595-606, 1986.
- 10 33 ACIP. General recommendations on immunization. MMWR 43: No. RR-1, 1994.
- 11 34 Barbi M, et al. Antibody response to inactivated polio vaccine (eIPV) in children born to
12 HIV positive mothers. Eur J Epidemiol 8: 211-216, 1992.
- 13 35 Varon D, et al. Response to hemophilic patients to poliovirus vaccination: Correlation with
14 HIV serology and with immunological parameters. J Med Virol 40: 91-95, 1993.
- 15 36 Vidor E, et al. Fifteen-years experience with vero-produced enhanced potency inactivated
16 poliovirus vaccine (eIPV). Ped Infect Dis J, 312-322, 1997.
- 17 37 Stratton, R. et al. Adverse Events Associated with Childhood Vaccines. Polio Vaccines.
18 National Academy Press, 295-299, 1994.
- 19 38 CDC. Vaccine Adverse Event Reporting System - United States. MMWR 39: 730-733,
20 1990.
- 21 39 CDC. National Childhood Vaccine Injury Act. Requirements for permanent vaccination
22 records and for reporting of selected events after vaccination. MMWR 37: 197-200, 1988.

- 1 40 Food & Drug Administration. New Reporting Requirements for Vaccine Adverse Events.
2 FDA Drug Bull 18 (2), 16-18, 1988.
- 3 41 Recommended childhood immunization schedule - United States, 1999. MMWR 48: 12-16,
4 1999.
- 5

1 Product Information as of May 2013.

2

3 Manufactured by:

4 Sanofi Pasteur SA

5 Lyon France

6 US Govt License #1724

7

8 Distributed by:

9 Sanofi Pasteur Inc.

10 Swiftwater PA 18370 USA

11 1-800-VACCINE (1-800-822-2463)

12

13

14

15